Second Primaries for Over 25% With Metastatic Prostate Cancer

This article originally appeared here.
Share this content:
Second Primaries for Over 25% With Metastatic Prostate Cancer
Second Primaries for Over 25% With Metastatic Prostate Cancer

THURSDAY, April 23, 2015 (HealthDay News) -- More than one-quarter of patients with metastatic prostate cancer present with a synchronous second primary malignancy, according to a review published in the April issue of The Journal of Urology.

Kyo Chul Koo, M.D., Ph.D., from the Yonsei University College of Medicine in Seoul, South Korea, and colleagues conducted a retrospective record review of 582 consecutive patents with prostate cancer diagnosed with metastasis. The authors examined the prognostic impact of a synchronous second primary malignancy, defined as a cytologically or histologically proven solid malignancy, on overall survival.

The researchers found that 28.1 percent of patients had a synchronous second primary malignancy, of which the most prevalent types were colorectal (9.1 percent), stomach (7.3 percent), and lung (7.1 percent) cancers. During a median follow-up of 34.1 months, the rate of overall survival was significantly higher for patients without a synchronous secondary primary malignancy versus those with lung or stomach cancer. Outcomes were comparable for men without a second malignancy and for those with colorectal cancer. Independent predictors of overall mortality included clinical stage T4 or greater, American Society of Anesthesiologists score 1 or greater, and lung or stomach cancer.

"A substantial proportion of patients with metastatic prostate cancer present with a synchronous second primary malignancy," the authors write. "Definitive therapy targeting prostate cancer may confer a limited survival benefit in patients with synchronous lung or stomach cancer."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »